Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by D.H. Fitchett
Consistent Cardiovascular (CV) Benefit of Empagliflozin Over the Spectrum of CV Risk Factor Control in EMPA-REG OUTCOME
Metabolism: Clinical and Experimental
Endocrinology
Metabolism
Diabetes
Related publications
EMPA-REG OUTCOME: The Endocrinologist's Point of View
American Journal of Medicine
Medicine
EMPA-REG OUTCOME: The Nephrologist's Point of View
American Journal of Cardiology
Cardiovascular Medicine
Cardiology
EMPA-REG OUTCOME: The Cardiologist's Point of View
American Journal of Cardiology
Cardiovascular Medicine
Cardiology
Following the Results of the EMPA-REG OUTCOME Trial With Empagliflozin, Is It Possible to Speak of a Class Effect?
International Journal of General Medicine
Medicine
Pdb62 - Cost-Effectiveness Analysis of Empagliflozin in Japan Based on Results From the Subgroup Analysis of Asian Patients in the Empa-Reg Outcome Trial
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Mortality Reduction in EMPA-REG OUTCOME Trial: Beyond the Antidiabetes Effect
Diabetes Care
Internal Medicine
Endocrinology
Advanced
Metabolism
Specialized Nursing
Diabetes
Empa's New Clothes: The Untold Story of the Empa-Reg Outcome Trial
Diabetes Technology and Therapeutics
Medicine
Endocrinology
Medical Laboratory Technology
Metabolism
Diabetes
DECLARE-TIMI 58 Trial in the Context of EMPA-REG OUTCOME and CANVAS
Diabetes Mellitus
Internal Medicine
Endocrinology
Metabolism
Diabetes
Erratum. Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials. Diabetes Care 2017;40:821–831
Diabetes Care
Internal Medicine
Endocrinology
Advanced
Metabolism
Specialized Nursing
Diabetes
